AQP4 and systemic lupus erythematosus: There is an urgent need to update our definition of myelitis in the context of lupus and other rheumatologic diseases now that we have entered an era of defining neurologic diagnoses based on specific biomarkers (e.g., AQP4-IgG in NMOSD), which identify patients with unique prognoses, monitoring, and treatment requirements.33